PAREXEL International Corp.

As Chairman and CEO of PAREXEL, which he founded in 1982, Mr. von Rickenbach has taken PAREXEL from its pioneering beginnings as one of the first clinical research organizations (CROs) more than two decades ago to its place as one of the top three public clinical service providers today. He has led PAREXEL through its IPO, multiple public offerings, and over 30 acquisitions during the Company’s history of more than 25 years to expand its portfolio in order to meet changing client needs and market demand. Under his leadership, PAREXEL has evolved to provide a broad range of services to the biopharmaceutical industry, including integrated clinical development, regulatory affairs consulting, commercialization services and technologies that expedite time-to-market. Foreseeing the globalization of clinical research, Mr. von Rickenbach has worked to expand PAREXEL’s global footprint to provide access to a wide array of geographies for clients’ programs. Mr. von Rickenbach has made several innovative contributions to the advancement of the biopharmaceutical services industry through PAREXEL, including conceiving of a complex, multi-disciplinary, systems-oriented approach to outsourced clinical development, bringing efficiencies, speed, scalability and standardization to the business. As part of the S-1 filing to the SEC, he was among the first to define the industry in formal terms. As the biopharmaceutical industry adopted information technology, Mr. von Rickenbach created a leading advanced technology offering, and today PAREXEL’s subsidiary Perceptive Informatics is a front runner in providing eClinical solutions. Mr. von Rickenbach’s extensive experience in the biopharmaceutical services industries puts him at the forefront of drug development and management. After having begun his career with Schering-Plough, Mr. von Rickenbach also held positions with ENSECO (formerly ERCO). Mr. von Rickenbach served as Chair of the Association of Clinical Research Organizations (ACRO) in 2005, and is a long-standing member of the ACRO Board of Directors. He also serves on the Board of Directors of the New England Healthcare Institute. Mr. von Rickenbach holds a B.S. degree in Business Economics from the School of Business at the Lucerne University of Applied Sciences in Switzerland, and a Master of Business Administration degree from Harvard University.

Mr. Rieder has more than 20 years of IT experience in translating business objectives into technological requirements and managing global IT organizations in application development and implementation as well as system integration. Prior to joining PAREXEL, Mr. Rieder was Vice President of Information Technology at Kos Pharmaceuticals, where he built a state-of-the-art, customer-centric IT division, determined IT strategy, and directed all corporate-wide IT initiatives. Previously, he held senior IT management positions at BRI International, a contract research organization, and at North American Vaccine, a provider of pediatric-based vaccines. Mr. Rieder holds an MBA in Information Technology from The American University in Washington, D.C. and a BSBA in Business Economics and Pre-Medicine from The University of Arizona. He is a member of the Society for Information Management. Mr. Rieder is a contributing author to the book Improving Technology ROI: Leading CTOs and CIOs on Making Successful Technology Investments, Maximizing Return on Investments & Gaining a Competitive Edge.

As Senior Vice President and CFO, Mr. Winschel is responsible for overseeing the worldwide financial management for PAREXEL. With more than 30 years of experience in financial and general management, Mr. Winschel has focused his energies on a variety of initiatives with the Company. He has led various profitability improvement initiatives, centralized cash management through the creation of a worldwide treasury function and implemented extensive upgrades to the Company’s management information systems. In addition, Mr. Winschel has simplified the financial infrastructure by eliminating more than 30 legal entities, substantially reducing the number of banks and mechanizing the manual processes, as well as ensuring the Company’s critical systems were EURO compliant. Prior to joining PAREXEL, Mr. Winschel served as President of U.B. Vehicle Leasing, Inc., a U.S.-based vehicle leasing division of BTM Capital Corporation, a subsidiary of The Bank of Tokyo-Mitsubishi, Ltd. Prior to assuming presidency of this division, he was appointed Executive Vice President and CFO of BTM Capital. Previously, Mr. Winschel held leadership positions at Caremark International, Inc., Whirlpool Financial Corporation, and General Electric Company. Mr. Winschel holds Bachelor’s and Master’s degrees in Finance and Accounting from Syracuse University.

With more than 20 years of experience in the biopharmaceutical industry, Dr. Schneider is responsible for the worldwide administrative functions at PAREXEL including Corporate Services, Information Technology, Human Resources, Facilities, Purchasing, and Regional Management. Prior to his current role, Dr. Schneider served in several senior executive positions at PAREXEL, including as Vice President of Finance and Administration for the Company and as Managing Director, PAREXEL Germany. Prior to joining PAREXEL, Dr. Schneider held financial management positions at Schering AG in Germany, where he was responsible for group finance in support of subsidiaries in Latin America and Europe. Dr. Schneider received his Master’s degree in Business Administration and Ph.D. in Business Management from the Berlin Technical University.

With more than 26 years of experience in regulatory and development strategy, Dr. Alberto Grignolo has helped numerous companies manage business risk by promoting effective regulatory strategies and relationships with regulators. Leading a global team of experts at PAREXEL Consulting, Dr. Grignolo oversees the management of regulatory submissions for clients with Regulatory Authorities worldwide. Dr. Grignolo has been an advocate for progress in personalized drug development, and has helped the industry recognize emerging opportunities to deliver safe and effective medicines to the right patients. Prior to joining PAREXEL, Dr. Grignolo served as President of FIDIA Pharmaceutical Corporation, and held management positions in regulatory affairs at Smith Kline & French Laboratories. He has served as an adviser to the Institute of Medicine of the National Academy of Sciences on human subject protection in clinical trials. He is currently a member of the Executive Committee of the Clinical Trials Transformation Initiative (CTTI). Dr. Grignolo has served as a leader of several industry organizations, including as Chairman of RAPS and on the Board of Directors for DIA. Dr. Grignolo holds a Ph.D. in Psychology from the University of North Carolina at Chapel Hill and a B.S. degree from Duke University. He completed postdoctoral work in neuropharmacology at Duke University Medical Center. He is currently Adjunct Associate Professor at the Massachusetts College of Pharmacy and Health Sciences.

Mr. Batt is Senior Vice President and General Counsel, as well as Secretary of the Corporation. In this capacity, Mr. Batt oversees the Company's worldwide corporate legal responsibilities as well as corporate governance matters. Mr. Batt brings to PAREXEL more than 15 years of corporate legal experience, as well as a prior business background. He has provided counsel on a wide range of matters including corporate governance, mergers and acquisitions, strategic alliances, financial transactions, intellectual property and regulatory affairs. Prior to joining PAREXEL, Mr. Batt was Executive Vice President and General Counsel at Concord Communications, a publicly-traded software company. Mr. Batt was previously Technology Counsel at Reebok International Ltd. and with the Boston law firm of Goodwin Procter in Boston. After attending Princeton University, Mr. Batt received his Bachelor's degree from the University of California, Berkeley. Mr. Batt received his J.D. degree from Boston University School of Law. Mr. Batt is a noted international speaker on technology-related issues and has presented at the United Nations and The Hague as well as at forums in Europe, Asia and South America.

Susan H. Alexander is our Executive Vice President, General Counsel and Corporate Secretary and has served in these positions since January 2006. Prior to that, Ms. Alexander had served as the Senior Vice President, General Counsel and Corporate Secretary of PAREXEL International Corp. since September 2003. From June 2001 to September 2003, Ms. Alexander served as General Counsel of IONA Technologies. From January 1995 to May 2001, Ms. Alexander served as Counsel at Cabot Corp. Prior to that, Ms. Alexander was a partner of the law firms of Hinckley, Allen & Snyder and Fine & Ambrogne.

Prior to joining PAREXEL, Dr. Piergies held positions in drug development at Pfizer (Germany and Austria), Wyeth-Ayerst Research (Philadelphia), Fujisawa (Illinois) and GlaxoSmithKline (North Carolina). He also worked as a consultant to the pharmaceutical industry. Throughout his career, he specialized in Clinical Pharmacology trials including First in Man studies. Dr. Piergies held faculty appointments at Northwestern University Medical School, the University of South Florida, the University of Pennsylvania School of Medicine and recently held the appointment of Associate Professor of Clinical Pharmacology in the Department of Medicine at Tulane University in New Orleans. He has contributed to numerous medical and scientific publications. Dr. Piergies is a licensed medical doctor and is board-certified in clinical pharmacology. He completed electrical engineering studies earning a Masters of Science degree in Electrical Engineering from Technische Hochschule, Magdeburg, Germany. He obtained his medical degree and postgraduate research degree in medicine at Ludwig Maximillian University, Munich, Germany.

Dr. Tardiff joins the organization after two and a half years with Merck & Co. where she was Executive Director, Research Information Services. She previously served as Vice President of Informatics, Data Management and Biostatistics at Regeneron Pharmaceuticals. Dr. Tardiff is certified by the American Board of Pediatrics and the American Board of Anesthesiology and completed a clinical research fellowship at the Duke Clinical Research Institute. She currently holds several prestigious consultancy appointments including Assistant Consulting Professor, Duke University School of Medicine and is an occasional lecturer at Fuqua School of Business, Duke University. She is a member of the Drug Information Association’s (DIA) Information Technology Track Program Committee and has been an active participant in various Health Information Technology forums. Dr. Tardiff is also active in industry standards initiatives such as CDISC and Health Level Seven (HL7), and served as co-chair of the HL7 Regulated Clinical Information Management Technical Committee for five years. Her research has been featured in numerous publications including the Journal of the American College of Cardiology and the American Heart Journal. Dr. Tardiff holds an MD from Yale University, an MBA from Duke University, Fuqua School of Business, an MS, M. Phil from Yale University, and a BS from Oregon State University. She is based at PAREXEL’s worldwide headquarters in Waltham, Massachusetts.

Mr. Stevens has more than 17 years of pharmaceutical and biotechnology industry experience. Prior to joining PAREXEL, Mr. Stevens held senior level reimbursement positions at Cephalon and Cell Therapeutics and sales positions at Genetics Institute and Abbott Laboratories. He has provided guidance on navigating through various aspects of the Medicare Modernization Act of 2003, including Medicare Part D, as well as numerous private payer policy changes. Mr. Stevens has significant experience in providing strategic reimbursement direction for products, whether they are administered by a healthcare professional (HCP administered) or self-administered. His expertise includes a broad range of therapeutic areas, including oncology, HIV/AIDS, addiction medicine, hormone replacement therapy, gastroenterology, and urology. Mr. Stevens holds a Bachelor’s degree from Northeastern University, an MBA from Clark University, and earned his Juris Doctor Degree from Suffolk University Law School in Boston, Massachusetts. He attended the Massachusetts Senior Executive Program at Harvard University’s John F. Kennedy School of Government, and has been admitted to the Massachusetts Bar.

Mr. Van Deusen joins PAREXEL from Publicis Groupe, one of the world’s largest communications companies, where he held several executive-level positions. Most recently, he served as Executive Vice President and Managing Director of the Saatchi & Saatchi Healthcare Division. Mr. Van Deusen also brings to PAREXEL extensive client-side experience, having held senior business management positions at Advanced Polymer Systems and Bausch & Lomb, as well as brand management positions at Procter & Gamble and SmithKline Beecham. Mr. Van Deusen is primarily based in Stamford, CT, and also manages global efforts from PAREXEL offices in Worthing, UK.

Professor Scholtz started his career in clinical pharmacology eleven years ago with FARMOVS, which was acquired by PAREXEL more than three years ago, and has held several scientific and senior management positions within the Clinical Pharmacology Network. Most recently, he held the position of Chief Executive Officer, FARMOVS-PAREXEL Clinical Research Organization in Bloemfontein, South Africa. As a clinical pharmacologist, Professor Scholtz was responsible for the establishment of a state-of -the-art glucose clamp unit in 1995, a pivotal advancement in the development and registration of various anti-diabetic and insulin products. Professor Scholtz is a trained anesthesiologist and holds degrees in medicine, MBChB, from the University of Pretoria, South Africa, and anesthesiology, MMed, received Cum Laude from the University of the Free State and is an anesthesiology fellow of the South African College of Medicine both located in South Africa. In a related development, Sybrand G. Pretorius, MBChB, MBA, was appointed Head of FARMOVS-PAREXEL in place of and reporting to Professor Scholtz. Dr. Pretorius assumes responsibility for the management of the unit’s bioanalytical laboratory and clinical pharmacology research facility comprised of 90 dedicated beds. Trials conducted at this unit include proof-of-concept, drug interaction, single and multiple dose, specialized PK/PD and biomarker, glucose clamp, spiro-ergometry, and bone densitometry studies. Dr. Pretorius earned his MBChB degree and Master’s degree in Pharmacology from the University of the Free State, South Africa. In addition, he possesses a Masters degree in Business Administration from Potchefstroom University, South Africa.

Prior to joining PAREXEL, Ms. Fisher was President of Gardiner-Caldwell U.S., a former business unit of Thomson Healthcare. Before leading the U.S. business unit, she was a Business Unit Manager within Thomson Healthcare’s medical communications group based in the U.K. Previously, Ms. Fisher held senior-level positions at Page & Moy Marketing in the U.K. She has extensive experience working on a variety of medical education and communications programs, involving content development and message delivery, for large, mid-size, and small and emerging biopharmaceutical companies, across a broad range of therapeutic areas, including oncology, neurology, HIV, psychiatry and dermatology. Ms. Fisher holds a Bachelor’s degree from University College London.

Prior to joining PAREXEL, Dr. Avellone was the former Chief Executive Officer of Veritas Medicine, a healthcare technology company supporting clinical research trials. Previously, he held senior management positions at Healthvision and served as Chief Operating Officer for BlueCross BlueShield of Massachusetts. With more than 20 years of experience in healthcare management, Dr. Avellone’s expertise includes establishment of strategic direction; developing and growing products, services and technologies; managing operations of major business lines; directing senior management teams; and managing major care networks and contractual relationships. Dr. Avellone is a Fellow of the American College of Surgeons, having received his M.D. from the Harvard Medical School, and completed his General Surgery Residency at Brigham and Women’s Hospital. He also received a Master’s degree in Public Administration from the John F. Kennedy School of Government at Harvard University, and a Bachelor’s degree from Dartmouth College. Dr. Avellone is based at PAREXEL’s worldwide headquarters in Waltham, Massachusetts.

Alain Eudaric is Director of Clinical Logistics Services at PAREXEL International.He joined PAREXEL International from ThermoFisher Scientific, where he held several management positions. Previously Mr. Eudaric was a management consultant at A.T.Kearney. Alain Eudaric holds an MBA from the Massachusetts Institute of Technology Sloan School of Management, a Master of Science from Purdue University and an Engineering Diploma from Ecole Centrale de Lille in France.

Before joining PAREXEL, Dr. Vornov held the positions of Senior Medical Director of Experimental Medicine at MGI Pharma, and Director of Clinical Development and Clinical Pharmacology at Guiford Pharmaceuticals, where he focused on the rapid transition of compounds into the clinic using biomarkers, pharmacokinetic and pharmacodynamic modeling, and clinical trial simulation. He has directed clinical development efforts in a number of disease areas including stroke and Parkinson’s Disease, as well as in the area of neuropathy and neuropathic pain. Dr. Vornov served on the faculty of Johns Hopkins School of Medicine in the Departments of Neurology and Neuroscience for 10 years. Dr. Vornov holds MD and Ph.D degrees from the Emory School of Medicine and completed his residency training at Johns Hopkins School of Medicine. He is Board Certified in Neurology. Dr. Vornov has authored numerous papers and book chapters and has spoken at international congresses on a wide array of neurological topics.

Eduard E. Holdener, M.D., 63, was elected as Director of the Company in January 2008, coinciding with his retirement from F. Hoffmann-La Roche, Ltd. in Basel Switzerland, after 22 years of service. From January 1999 until his retirement, Dr. Holdener served as Head of Global Pharmaceutical Development and also served as the Company’s Chief Medical Officer. During his career with the Company, he helped to establish and expand the oncology therapeutic area, and led the Company’s development operations in Japan for several years in the late 90’s. Prior to joining Roche, Dr. Holdener held positions as a clinical oncologist in hospital settings and academic institutions, both in Switzerland and the United States. Dr. Holdener received his Medical Degree from the University of Zurich and Basel Medical School in Switzerland, and completed his fellowship in Oncology at the University of Kansas Medical Center in the United States. He is Board Certified in Internal Medicine and Oncology/Hematology in Switzerland.

Dick's career spans 38 years with more than 24 years of leadership roles in the oncology focused biosciences. He is presently the Managing Director of TGen Accelerators, LLC. He started two biopharmaceutical companies, Triton Biosciences Inc. and ILEX Oncology Inc. (ILXO) and served as CEO in both companies for periods of 8 years each. In addition, Dick has served in executive positions at not-for-profit organizations, including the Cancer Therapy and Research Center (CTRC), The San Antonio Technology Accelerator Initiative (SATAI) and the Translational Genomics Research Institute (TGen). Dick joined TGen in January 2003 as its Chief Operating Officer. At Triton and ILEX, Dick led teams that were responsible for the clinical development of multiple important therapeutic products; four or which are currently in the practice of medicine: Betaseron for patients with multiple sclerosis; Fludara and CAMPATH , both for patients with chronic lymphocytic leukemia; and, Clolar for acute lymphocytic leukemia. In 2004 ILEX was acquired by Genzyme Corporation in a stock for stock transaction valued at approximately $1.0 billion. Dick also serves on the Boards of Directors of Parexel International (PRXL) and Xilas Medical.